A growth factor receptor is a receptor that binds to a growth factor.[1] Growth factor receptors are the first stop in cells where the signaling cascade for cell differentiation and proliferation begins. Growth factors, which are ligands that bind to the receptor are the initial step to activating the growth factor receptors and tells the cell to grow and/or divide.
These receptors may use the JAK/STAT, MAP kinase, and PI3 kinase pathways.[2]
A majority of growth factor receptors consists of receptor tyrosine kinases (RTKs). There are 3 dominant receptor types that are exclusive to research : the epidermal growth factor receptor, the neurotrophin receptor, and the insulin receptors.[3] All growth factor receptors are membrane bound and composed of 3 general protein domains: extracellular, transmembrane, and cytoplasmic.[4] The extracellular domain region is where a ligand may bind, usually with very high specificity.[5] In RTKs, the binding of a ligand to the extracellular ligand binding site leads to the autophosphorylation of tyrosine residues in the intracellular domain.[6] These phosphorylations allow for other intracellular proteins to bind to with the phosphotyrosine-binding domain which results in a series of physiological responses within the cell.[6]
YouTube Encyclopedic
-
1/5Views:4 32150 36926 37110 59510 040
-
The Growth Factor Receptor and MAPK / ERK Pathway Part 3
-
EGFR Mode of Action
-
EGF Signal Transduction Pathway
-
Epidermal growth factor
-
Insulin and IGF Signaling Receptors (IGF-1R) and Pathway Activation
Transcription
Medical relevance
Research in today’s society focus on growth factor receptors in order to pinpoint cancer treatment. Epidermal growth factor receptors are involved heavily with oncogene activity.[7] Once growth factors bind to their receptor, a signal transduction pathway occurs within the cell to ensure the cell is working. However, in cancerous cells, the pathway might never turn on or turn off.[7] Furthermore, in certain cancers, receptors (such as RTKs) are often observed to be overexpressed, which corresponds to the uncontrolled proliferation and differentiation of cells.[8] For this same reason, tyrosine receptors are often a target for cancer therapy.[8]
References
- ^ Growth+Factor+Receptors at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- ^ A. V. Hoffbrand; P. A. H. Moss; J. E. Pettit (2006). Essential haematology. Wiley-Blackwell. pp. 6–. ISBN 978-1-4051-3649-5. Retrieved 28 November 2010.
- ^ McInnes, Campbell; Sykes, Brian D. (1997). "Growth factor receptors: Structure, mechanism, and drug discovery". Peptide Science. 43 (5): 339–366. doi:10.1002/(SICI)1097-0282(1997)43:5<339::AID-BIP2>3.0.CO;2-W. ISSN 1097-0282. PMID 9566117.
- ^ Goodman, Steven R., ed. (2008-01-01), "Chapter 7 - Intercellular Signaling", Medical Cell Biology (Third Edition), Academic Press, pp. 227–248, doi:10.1016/B978-0-12-370458-0.50012-8, ISBN 978-0-12-370458-0, retrieved 2020-04-29
- ^ Kouvidi, Katerina; Nikitovic, Dragana; Berdiaki, Aikaterini; Tzanakakis, George N. (2014-01-01), Simpson, Melanie A.; Heldin, Paraskevi (eds.), "Chapter Twelve - Hyaluronan/RHAMM Interactions in Mesenchymal Tumor Pathogenesis: Role of Growth Factors", Advances in Cancer Research, Hyaluronan Signaling and Turnover, 123, Academic Press: 319–349, doi:10.1016/B978-0-12-800092-2.00012-5, PMID 25081535, retrieved 2020-04-29
- ^ a b Trenker, Raphael; Jura, Natalia (2020-04-01). "Receptor tyrosine kinase activation: From the ligand perspective". Current Opinion in Cell Biology. 63: 174–185. doi:10.1016/j.ceb.2020.01.016. ISSN 0955-0674. PMC 7813211. PMID 32114309.
- ^ a b Sasaki, Takamitsu; Hiroki, Kuniyasu; Yamashita, Yuichi (2013). "The Role of Epidermal Growth Factor Receptor in Cancer Metastasis and Microenvironment". BioMed Research International. 2013: 546318. doi:10.1155/2013/546318. ISSN 2314-6133. PMC 3748428. PMID 23986907.
- ^ a b Bennasroune, Amar; Gardin, Anne; Aunis, Dominique; Crémel, Gérard; Hubert, Pierre (2004-04-01). "Tyrosine kinase receptors as attractive targets of cancer therapy". Critical Reviews in Oncology/Hematology. 50 (1): 23–38. doi:10.1016/j.critrevonc.2003.08.004. ISSN 1040-8428. PMID 15094157.
This page was last edited on 29 April 2024, at 15:41